|
|
Article: Prana's Open Label Extension Study of PBT-1 Reinforces Positive Phase II Results.
- Article from:
- PR Newswire
- Article date:
- October 12, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- PBT-1 Slows Alzheimer's Disease Progression and Well Tolerated by Patients -
Prana Biotechnology Limited , today announced the results of the open label 84-week "Extension Study" of its Phase II clinical trial of PBT-1 (clioquinol) study, also known as the CQAD study. The data from the formal treatment phase of the study was published in the December 2003 issue of Archives of Neurology.
All participants from the original 36-week blinded and placebo-controlled portion of the Phase II trial were offered the opportunity to continue the PBT-1 treatment on an open label basis for an additional 48 weeks. 18 (66.7%) out of 27 patients elected to start the ...